Mammalian asparagine synthetase is a glutamine-dependent amidotransferase. Efforts to identify an effective inhibitor of human asparagine synthetase for use in chemotherapy for patients with leukemia have focused not on the amino-terminal glutaminase domain but on the carboxyl-terminal synthetase active site. Explain why the glutaminase domain is not a promising target for a useful drug.